Markets benign reaction to Trump's latest tariffs is puzzling
market
reaction to
Donald Trump's
latest
tariff
announcements – which applied massive import levies to dozens of countries including up to 50 per cent on India and Brazil – is hard to comprehend.
Despite the assault on global trade and the ongoing uncertainty around
US policy
, most major indices traded near record highs last week.
Trump claimed his tariffs were having a 'huge positive impact on the stock market' while boasting about how much revenue the US would generate from them when, in fact, the levies represent a stealth tax on US consumers.
On the back of a relatively positive results season in the US, when more companies reported figures that beat market expectations, the markets – at least in the US – seem to be suggesting that the tailwinds from Trump's tax cuts and deregulation are outweighing the potential headwinds from tariffs.
READ MORE
Or is it that markets have their collective head in the sand on tariffs and the reversing job numbers in the US?
Back in April when Trump unveiled his so-called
'Liberation Day' tariffs
and the weird economic calculations that underpinned them, a black hole opened up in front of White House.
As stocks plummeted, investors sold US bonds when, historically, they should have been buying them. Investors typically flee to safe-haven US bonds when stocks weaken but this time it was different, the US was on a reckless path, a trade-wrecking, fiscally-irresponsible path, or so the markets told us.
In what was dubbed 'America's Liz Truss moment', Trump blinked, putting a stay on his tariff plan.
Now, Trump is back with the same plan and bigger-than-expected tariff rates on dozens of countries, including 15 per cent on EU imports, but the market reaction is benign.
What has changed?
Markets are all about future expectations. Do they now believe the US economy and the global economy can handle higher costs and Trump's uncertain economic narrative?
Or are they frothy because they believe the Fed Funds will soon be cutting rates?
Or is it, as many contend, that they believe Trump will back away from the worst of his agenda when the US economy starts to sour, the so-called Taco (Trump also chickens out) dynamic?
No one knows and that makes it very hard to pin down the current market dynamic.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Sunday World
3 hours ago
- Sunday World
State sends National Guard members to Washington at Trump team's request
The move by a nearby state comes as hundreds of District of Columbia National Guard were activated this week to back up local law enforcement US President Donald Trump gestures as he boards Air Force One (Julia Demaree Nikhinson/AP) West Virginia is sending 300 to 400 members of its National Guard to the US capital to assist in the Trump administration's takeover of the city's police department. The move by a nearby state comes as hundreds of District of Columbia National Guard were activated this week to back up local law enforcement in what the Republican administration calls an effort to crack down on crime and homelessness in the District of Columbia. Governor Patrick Morrisey said in a post on Saturday on X that he was deploying '300-400 skilled personnel' from the West Virginia National Guard to support Mr Trump's 'initiative to make DC safe and beautiful'. Mr Morrisey said the step reflects 'our commitment to a strong and secure America'. They will arrive in the District of Columbia along with equipment and specialised training services, his office said in a statement. 'West Virginia is proud to stand with President Trump in his effort to restore pride and beauty to our nation's capital,' Mr Morrisey said. 'The men and women of our National Guard represent the best of our state, and this mission reflects our shared commitment to a strong and secure America.' US President Donald Trump gestures as he boards Air Force One (Julia Demaree Nikhinson/AP) News in 90 Seconds - August 16th The move comes as federal agents and National Guard troops have begun to appear across the heavily Democratic city after Mr Trump's executive order on Monday federalising local police forces and activating about 800 DC National Guard troops for his plan. Maj Gen James Seward, West Virginia's adjutant general, said in a statement that members of the state's National Guard 'stand ready to support our partners in the National Capital Region' and that the Guard's 'unique capabilities and preparedness make it an invaluable partner in this important undertaking.' Federal agents have appeared in some of the city's most highly trafficked neighbourhoods, garnering praise, pushback and alarm from local residents and leaders across the country. City leaders, who are obliged to co-operate with the president's order under the federal laws that direct the district's local governance, have sought to work with the administration though have bristled at the scope of the president's takeover.
Extra.ie
5 hours ago
- Extra.ie
Nothing given away after three hour summit in Alaska
President Trump has described his meeting with Russian President Vladamir Putin as one in which they made 'great progress' in talks aimed at ending the war in Ukraine. The two men met for a 3 hour discussion in Alaska where President Trump said they 'agreed on many many points, but there is no deal, until there's a deal'. Neither leader mentioned any details of what was discussed, or if there had been anything productive to take forward to the next meeting, but Trump said his next move would be to contact Ukrainian President Volodomyr Zelensky, and key European Allies to discuss the negotiations. ANCHORAGE, ALASKA – AUGUST 15: U.S. President Donald Trump (R) walks with Russian President Vladimir Putin as they arrives at Joint Base Elmendorf-Richardson on August 15, 2025 in Anchorage, Alaska. The two leaders are meeting for peace talks aimed at ending the war in Ukraine. (Photo by) 'There were many, many points that we agreed on, most of them,' Trump said at a press conference, where neither he nor Putin took any questions from the media. President Putin also described the meeting as productive and claimed repeatedly that the men had come to an understanding', however no details of any such understanding were made public. Putin added that he hoped 'today's understanding will be the starting point not only for the solution of the Ukrainian issue, but also will help us bring back business-like and pragmatic relations between Russia and the US.' ANCHORAGE, ALASKA – AUGUST 15: U.S. President Donald Trump (R) and Russian President Vladimir Putin hold a press conference at Joint Base Elmendorf-Richardson on August 15, 2025 in Anchorage, Alaska. The two leaders are meeting for peace talks aimed at ending the war in Ukraine. (Photo by) Only a few hours earlier, Donald Trump had said that anything short of an immediate cease-fire would be unsatisfactory. Speaking to reporters on board Air Force One, on his way to the meeting he said 'I want to see a cease-fire rapidly. I don't know if it's going to be today, but I'm not going to be happy if it's not today.' 'Everyone said it can't be today, but I'm just saying, I want the killing to stop. I'm in this to stop the killing.' He also said that he would not agree to affirm Russia's hold over parts of Ukraine, and said he would leave those kinds of decisions to the powers that be in Kyiv.
Irish Times
6 hours ago
- Irish Times
Gareth Sheridan: Nutriband ‘will help a lot of people who are dealing with addiction and people who are dealing with pain'
Nutriband is a pharmaceutical company that was founded in Dublin in 2012 before relocating to Florida in 2016. Gareth Sheridan, who recently announced his intention to run for president and has stepped aside for three months as chief executive, is its founder. The company's lead product is Aversa, which it describes as 'abuse-deterrent transdermal technology', which incorporates aversive agents to prevent the abuse, diversion, misuse, and accidental exposure of drugs with abuse potential, specifically opioids. Its first application is its abuse-deterrent fentanyl transdermal patch, which it is developing to provide clinicians and patients with extended-release chronic pain relief. It is awaiting regulatory clearance for this product in the US. The company has operations in Florida, Georgia, and North Carolina, and recently began its expansion back to Dublin. READ MORE What lightbulb moment prompted you to start-up in business? It was originally a thesis idea. I had noticed a patch that my dad wears and began wondering what other types of medications could be delivered that way that had not been explored yet. The thesis became a business plan, and Nutriband was registered in 2012. Describe your business model and what makes your business unique. We structured the company in a unique way, using capital markets and a public listing approach. We listed on the OTC Markets in 2016 and started using stock to purchase companies and technologies in place of cash. This helped us to avoid raising expensive early capital and retain a major equity stake in the company today, even after an eventual qualification to list on the Nasdaq (in New York) in 2010. We also do not develop new drug applications. We take existing generic medications and use our technologies to improve upon those and relaunch them as a branded product again. What is your greatest business achievement to date? Growing the company to a level where we qualified to list on the Nasdaq Stock Exchange and getting to ring the opening bell. What was your back-to-the-wall moment and how did you overcome it? We almost got sued by the SEC (The US Securities and Exchange Commission) for an accidental erroneous disclosure in one of our filings while on the OTC markets. At first, we thought it could be explained. However, it grew to the point where they were doubling down. We hired an excellent attorney with SEC experience and eventually settled the issue in a cease-and-desist, no-admit, no-deny agreement. This led to our back-to-the-wall moment, where, while running on fumes financially, we received a rejection from Nasdaq in our first application. After a couple of days of self-pity, we got back to work, raised some working capital with existing shareholders, and grew the company's equity by $7.5 million (€6.4 million) over the course of the next year. We reapplied to list again successfully. What moment would you cite as a turning point for the company? Credibility provided by our Nasdaq listing and subsequent partnership with Kindeva Drug Delivery (formerly 3M Drug Delivery), where Kindeva supplied their generic approved fentanyl patch for us to add our technology to. What were the best and the worst pieces of advice you received when starting out? The worst advice was that banks and institutions have your company's best interests at heart. I firmly believe that today, Wall Street is built on companies failing, not succeeding. Describe your growth funding path. We were reluctant to raise expensive capital early on and instead listed the company to use stock as an acquisition currency to grow. Our gamble on this paid off, and although we raised modest cash along the way, we were able to build Nutriband without any significant seed or angel rounds. We reached a market capitalisation of $120 million (its market value currently is about $75 million), and we have been able to maintain stable and steady control as a result of the minimal capital rounds. We turn down anywhere from $5 million to $15 million on a weekly basis from funds and institutions because we do not need it. We are not in the business of raising money, and having as little dilution as possible is a core focus for us as a company. How will your market look in three years and where would you like your business to be? For our first product, we are expected to reach annual revenues of $200 million. Our second product is independently estimated to have upwards of $135 million in yearly revenue. We are targeting the billion dollar club before the end of 2027. What are your annual revenues and profits? We are not yet profitable, as is typical with clinical development-stage companies. However, we also contract manufacture sports tapes and products for brands such as Reebok and KT Tape. Our target revenue from this source for the financial year to the end of January 2026 is $3 million * . This goes towards operational costs and reduces our clinical burn. Why have you decided to seek a nomination for the presidency? It's never been a more important or relevant time in our history for a young president, particularly with the average age just under 40. I would be hoping that having a younger president would help narrow the division we're seeing in the country at the moment and that we can work together to tackle the issues, particularly the housing crisis. The younger generation aren't feeling very enthusiastic that their voices are being heard. What impact will this move have on your business? The company is in very safe hands and the biggest asset at the company is the team. We've got a very definite plan and timeline between now and Christmas on what needs to be achieved. Whether I'm in there or not that timeline needs to be adhered to. The company is motoring along fine. Stepping aside is not something that I think will fundamentally affect the opportunity for the company. What happens if you win? There are mechanisms where I can put the shares into a trust. I would be very proud that it was a company that I started and be very keen to still follow the journey, just not as CEO. Nutriband as a whole is going to do a lot of will help a lot of people who are dealing with addiction and people who are dealing with pain. *An earlier version of this article stated a higher target figure for contract manufacturing, which has since been revised by the company.
